Crispr Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$56.16 – a decrease of 7.43% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
CRISPR Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before the split, the next day you would own 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.
| 52-week range | US$37.55 - US$91.1 |
|---|---|
| 50-day moving average | US$73.3334 |
| 200-day moving average | US$59.5007 |
| Target price | US$85.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.94 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $56.16
| 1 week (2024-04-12) | -7.43% |
|---|---|
| 1 month (2024-03-19) | -21.96% |
| 3 months (2024-01-19) | -9.40% |
| 6 months (2023-10-19) | 41.18% |
| 1 year (2023-04-19) | 5.01% |
|---|---|
| 2 years (2022-04-19) | -4.75% |
| 3 years (2021-04-19) | -51.18% |
| 5 years (2019-04-18) | 54.88% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$37.55 up to US$91.1. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 1.743. This would suggest that CRISPR Therapeutics's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
| Revenue TTM | US$371.2 million |
|---|---|
| Operating margin TTM | 34.58% |
| Gross profit TTM | US$-570,697,000 |
| Return on assets TTM | -6.22% |
| Return on equity TTM | -8.17% |
| Profit margin | -41.38% |
| Book value | 23.522 |
| Market capitalisation | US$4.9 billion |
TTM: trailing 12 months
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
